Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke
- PMID: 17143191
- DOI: 10.1097/01.hjh.0000254376.80864.d3
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke
Abstract
Objective: The effects of candesartan treatment starting early (3 h) and delayed (24 h) after middle cerebral artery occlusion (MCAO) with reperfusion was investigated in normotensive rats.
Methods: Subcutaneous treatment with candesartan (0.3 and 3 mg/kg) or vehicle was initiated 3 or 24 h after the onset of MCAO and continued for seven consecutive days (n=20 per group and timepoint). Neurological outcome was evaluated daily using two different scoring systems. Infarct and oedema volumes were determined in rats 2 or 7 days after MCAO. Mean arterial, systolic and diastolic blood pressures were recorded before and after the application of candesartan.
Results: Mean arterial, systolic and diastolic blood pressures were markedly decreased with the high dose, but only moderately decreased with the low dose of candesartan. Vehicle-treated rats showed marked neurological deficits 24 h after MCAO, which gradually improved with time. Candesartan improved neurological outcomes at all timepoints only when treatment was started 3, but not 24 h after MCAO. The infarct volume was reduced on days 2 and 7 after MCAO in rats treated with the low but not the high dose of candesartan.
Conclusion: The present study demonstrates that only an early but not a delayed onset of treatment with candesartan exerts neuroprotection after focal ischaemia. The degree of neurological impairments did not correlate with the infarct volume, which was reduced only after the low dose of candesartan. The high dose of candesartan failed to reduce the infarct volume, probably because of an excessive blood pressure decrease.
Similar articles
-
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.J Hypertens. 2008 Mar;26(3):544-52. doi: 10.1097/HJH.0b013e3282f2dac9. J Hypertens. 2008. PMID: 18300867
-
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.Hypertens Res. 2009 Jul;32(7):548-53. doi: 10.1038/hr.2009.69. Epub 2009 May 8. Hypertens Res. 2009. PMID: 19424281
-
Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.J Hypertens. 2007 Apr;25(4):855-9. doi: 10.1097/HJH.0b013e3280149708. J Hypertens. 2007. PMID: 17351379
-
Inhibiting angiotensin receptors in the brain: possible therapeutic implications.Curr Med Res Opin. 2003;19(5):449-51. doi: 10.1185/030079903125001974. Curr Med Res Opin. 2003. PMID: 13678486 Review.
-
Neurological protection provided by candesartan: reviewing the latest study results.Curr Med Res Opin. 2003;19(5):445-8. doi: 10.1185/030079903125001974. Curr Med Res Opin. 2003. PMID: 13678485 Review.
Cited by
-
Elevated blood pressure in the acute phase of stroke and the role of Angiotensin receptor blockers.Int J Hypertens. 2013;2013:941783. doi: 10.1155/2013/941783. Epub 2013 Jan 31. Int J Hypertens. 2013. PMID: 23431423 Free PMC article.
-
Attenuation of focal cerebral ischemic injury following post-ischemic inhibition of angiotensin converting enzyme (ACE) activity in normotensive rat.Iran Biomed J. 2012;16(4):202-8. doi: 10.6091/ibj.1096.2012. Iran Biomed J. 2012. PMID: 23183619 Free PMC article.
-
Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia.Neurochem Res. 2018 Oct;43(10):1869-1878. doi: 10.1007/s11064-018-2604-x. Epub 2018 Aug 7. Neurochem Res. 2018. PMID: 30088238 Free PMC article.
-
Artery reopening is required for the neurorestorative effects of angiotensin modulation after experimental stroke.Exp Transl Stroke Med. 2016 Apr 27;8:4. doi: 10.1186/s13231-016-0018-x. eCollection 2016. Exp Transl Stroke Med. 2016. PMID: 27127602 Free PMC article.
-
The role of angiotensin II receptors in stroke protection.Curr Hypertens Rep. 2012 Jun;14(3):202-8. doi: 10.1007/s11906-012-0257-8. Curr Hypertens Rep. 2012. PMID: 22447068 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical